Eli Lilly and Co/ US5324571083 /
2024-11-12 10:10:00 PM | Chg. -13.58 | Volume | Bid1:59:36 AM | Ask1:59:36 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
818.86USD | -1.63% | 3.38 mill. Turnover: 1.67 bill. |
818.00Bid Size: 1,300 | 820.00Ask Size: 100 | 777.36 bill.USD | 0.57% | 140.70 |
Newsfile Corp
09-16
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Newsfile Corp
08-28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
08-27
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire
08-21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
08-21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
08-14
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
08-14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08-08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-08
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
08-07
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
08-06
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
08-06
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire
08-02
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
08-01
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
08-01
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives